A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of CORT113176 (Dazucorilant) in Patients With Amyotrophic Lateral Sclerosis (DAZALS)
Latest Information Update: 20 Jun 2025
At a glance
- Drugs Dazucorilant (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms DAZALS
- Sponsors Corcept Therapeutics
Most Recent Events
- 05 Jun 2025 According to a Corcept Therapeutics media release, company presented results at the European Network to Cure ALS (ENCALS) 2025 annual meeting.
- 05 Jun 2025 Results published in the Corcept Therapeutics media release.
- 11 Dec 2024 According to a Corcept Therapeutics media release, company will present Complete results from the DAZALS study will be presented at a medical conference next year.